Basel, Switzerland – A unique leadership dynamic is taking shape in the pharmaceutical world as Novartis CEO Vas Narasimhan and Idorsia CEO Srishti Gupta lead their respective companies. The pair represent a noteworthy “power couple” within the Basel-based pharmaceutical industry, a distinction highlighted by Swiss broadcaster SRF.
Gupta’s appointment as CEO of Idorsia, effective July 1, 2026, marks a significant shift for the biotechnology firm, which has faced ongoing financial challenges since its founding in 2017. She takes the helm after the unexpected departure of André C. Muller, who was promoted to CEO from CFO in mid-June 2024, according to reporting from the NZZ.
Narasimhan, who has led Novartis since 2018, has overseen a period of growth for the company following a strategic shift towards innovative medicines and away from generic drugs. In the past year, Novartis reported a robust 11 percent increase in revenue, marking the second consecutive year of strong growth, as reported by SRF.
Srishti Gupta’s Path to Idorsia Leadership
Although Gupta has maintained a relatively low profile in recent years, her role on Idorsia’s board of directors since 2021 signaled a growing involvement with the company. Her appointment comes as Idorsia seeks to overcome persistent losses and regain a foothold in the competitive biotechnology landscape. The NZZ reports that Idorsia originally aimed to reach profitability and exceed one billion Swiss francs in revenue in 2025, but those goals remain unrealized.
Gupta’s task is to steer Idorsia towards success, a challenge she appears prepared to tackle. According to an interview with FuW, Gupta intends to pursue further licensing deals as a key strategy for the company’s future. This approach suggests a focus on leveraging Idorsia’s research and development capabilities through strategic partnerships.
The Narasimhan-Gupta Dynamic
Vas Narasimhan, born August 26, 1976, in Pittsburgh, Pennsylvania, is an American physician who joined Novartis in 2005 after a brief period at McKinsey. He succeeded Joseph Jimenez as CEO of Novartis in 2018. His parents, who immigrated to the United States from India in the 1960s and 1970s, were influential in his upbringing, establishing the Shri Venkateshwara temple in Penn Hills, Pittsburgh. Narasimhan holds a bachelor’s degree from the University of Chicago, an M.D. From Harvard Medical School, and a master’s degree in public policy from the John F. Kennedy School of Government, as detailed in his Wikipedia entry.
The couple’s professional alignment is unusual in the pharmaceutical industry, creating a unique power dynamic within Basel’s business community. SRF describes them as a “worldwide unique duo.”
Looking Ahead for Novartis and Idorsia
The coming months will be critical for both Novartis and Idorsia. For Novartis, maintaining its growth trajectory and continuing to innovate will be paramount. For Idorsia, Gupta’s leadership will be closely watched as she implements her strategy to revitalize the company and achieve financial stability. The success of both companies will undoubtedly have a significant impact on the broader pharmaceutical landscape in Switzerland and beyond.
What impact will Srishti Gupta’s leadership have on Idorsia’s financial performance? Share your thoughts in the comments below, and please share this article with your network.
